(The annual meeting was held Nov. 3-8 in Boston.) | ||||
Company (Location) |
Product |
Description |
Indication |
Status (Date)# |
Baxter International Inc. (Deerfield, Ill.) |
HyQ |
A combination immunoglobulin product |
Bacterial infections |
Phase III data showed patients with primary immunodeficiencies had a reduced rate of serious bacterial infections when treated with HyQ (11/8) |
CSL Behring LLC (King of Prussia, Pa.) |
Berinert |
C1-esterase inhibitor |
Hereditary angioedema |
Data showed median time of 0.46 hours to the onset of symptom relief and 15.5 hours to resolution (11/8) |
Dyax Corp. (Cambridge, Mass.) |
Kalbitor |
Ecallantide; A plasma kallikrein inhibitor |
Hereditary angioedema |
Clinical data showed it remained effective across multiple episodes of acute HAE attacks with no apparent increase in adverse events (11/8) |
Sunovion Pharmaceuticals Inc. (Marlborough, Mass.) |
Ciclesonide |
Nasal aerosol; a corticosteroid formulated with a hydrofluoroalkane propellant |
Perennial allergic rhinitis |
Phase III data showed statistically significant improvements in reflective and instantaneous nasal symptoms after the first six weeks compared to placebo, as well as tolerability over 26 weeks (11/8) |
|
Notes: Public biotech company stock symbols can be found in the stock report located on the last two pages of this issue. # The date indicated refers to the BioWorld Today issue in which the news item can be found. | ||||